Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia

We retrospectively studied 97 acute myeloid leukemia patients with trisomy 19 (median age at diagnosis 57 years; range, 17- 83 years) treated between 2001 and 2019 within two multicenter study groups. Trisomy 19 occurred alone in ten (10.5%) patients, with additional abnormalities being present in n...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kayser, Sabine (VerfasserIn) , Ho, Anthony Dick (VerfasserIn) , Baldus, Claudia (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn) , Bornhäuser, Martin (VerfasserIn) , Röllig, Christoph (VerfasserIn) , Schlenk, Richard Friedrich (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: February 23, 2023
In: Haematologica
Year: 2023, Jahrgang: 108, Heft: 8, Pages: 2059-2066
ISSN:1592-8721
DOI:10.3324/haematol.2022.282127
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3324/haematol.2022.282127
Verlag, lizenzpflichtig, Volltext: https://haematologica.org/article/view/haematol.2022.282127
Volltext
Verfasserangaben:Sabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, Mathias Hänel, Mar Tormo, Kerstin Schäfer-Eckart, Carmen Botella, Friedrich Stölzel, Teresa Bernal del Castillo, Ulrich Keller, Carlos Rodriguez-Medina, Gerhard Held, Maria-Luz Amigo, Christoph Schliemann, Mercedes Colorado, Martin Kaufmann, Manuel Barrios Garcia, Stefan W. Krause, Martin Görner, Edgar Jost, Björn Steffen, Sven Zukunft, Uwe Platzbecker, Anthony D. Ho, Claudia D. Baldus, Hubert Serve, Carsten Müller-Tidow, Christian Thiede, Martin Bornhäuser, Pau Montesinos, Christoph Röllig and Richard F. Schlenk

MARC

LEADER 00000caa a2200000 c 4500
001 1865701548
003 DE-627
005 20240307050118.0
007 cr uuu---uuuuu
008 231016s2023 xx |||||o 00| ||eng c
024 7 |a 10.3324/haematol.2022.282127  |2 doi 
035 |a (DE-627)1865701548 
035 |a (DE-599)KXP1865701548 
035 |a (OCoLC)1425210187 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kayser, Sabine  |d 1979-  |e VerfasserIn  |0 (DE-588)138694923  |0 (DE-627)605256233  |0 (DE-576)30778813X  |4 aut 
245 1 0 |a Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia  |c Sabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, Mathias Hänel, Mar Tormo, Kerstin Schäfer-Eckart, Carmen Botella, Friedrich Stölzel, Teresa Bernal del Castillo, Ulrich Keller, Carlos Rodriguez-Medina, Gerhard Held, Maria-Luz Amigo, Christoph Schliemann, Mercedes Colorado, Martin Kaufmann, Manuel Barrios Garcia, Stefan W. Krause, Martin Görner, Edgar Jost, Björn Steffen, Sven Zukunft, Uwe Platzbecker, Anthony D. Ho, Claudia D. Baldus, Hubert Serve, Carsten Müller-Tidow, Christian Thiede, Martin Bornhäuser, Pau Montesinos, Christoph Röllig and Richard F. Schlenk 
264 1 |c February 23, 2023 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 15.11.2023 
520 |a We retrospectively studied 97 acute myeloid leukemia patients with trisomy 19 (median age at diagnosis 57 years; range, 17- 83 years) treated between 2001 and 2019 within two multicenter study groups. Trisomy 19 occurred alone in ten (10.5%) patients, with additional abnormalities being present in non-complex karyotypes in eight (8%) patients and in complex karyotypes in 79 (82%) patients. Altogether, karyotypes characterized by trisomies only were present in 27 (28%) patients. Data on response and outcome of intensively treated patients were available for 92 cases. The median follow-up was 6.4 years (95% confidence interval [95% CI]: 2.9-9.0 years). The complete remission (CR) rate after induction therapy was 52% (48 patients); the early death rate was 10% (n=9). Notably, patients with trisomy 19 as the sole abnormality had a CR rate of 89%. Allogeneic hematopoietic stem cell transplantation (allo-HCT) was performed in 34 (35%) patients (CR, n=19; active disease, n=15). Five-year relapse-free and overall survival rates were 26% (95% CI: 16-43%) and 20% (95% CI: 13-31%), respectively. Overall survival rates were significantly higher in patients with trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only (P=0.05). An Andersen-Gill model including allo-HCT as a time-dependent covariable on overall survival revealed that trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only was a favorable factor (hazard ratio [HR]=0.47; P=0.021); higher age at diagnosis had an adverse impact (10 years difference; HR=1.29; P=0.002), whereas allo-HCT did not have a beneficial impact (odds ratio=1.45; P=0.21). In our cohort, patients with trisomy 19 as the sole abnormality or within karyotypes characterized by trisomies only had a high CR rate and better clinical outcome. 
700 1 |a Ho, Anthony Dick  |d 1948-  |e VerfasserIn  |0 (DE-588)108692477  |0 (DE-627)504904205  |0 (DE-576)19010466X  |4 aut 
700 1 |a Baldus, Claudia  |d 1972-  |e VerfasserIn  |0 (DE-588)122672631  |0 (DE-627)705995054  |0 (DE-576)293374945  |4 aut 
700 1 |a Müller-Tidow, Carsten  |d 1968-  |e VerfasserIn  |0 (DE-588)1015101798  |0 (DE-627)705330230  |0 (DE-576)351197893  |4 aut 
700 1 |a Bornhäuser, Martin  |d 1966-  |e VerfasserIn  |0 (DE-588)1167559118  |0 (DE-627)1031176071  |0 (DE-576)511198817  |4 aut 
700 1 |a Röllig, Christoph  |d 1971-  |e VerfasserIn  |0 (DE-588)122493168  |0 (DE-627)705929116  |0 (DE-576)293296049  |4 aut 
700 1 |a Schlenk, Richard Friedrich  |d 1965-  |e VerfasserIn  |0 (DE-588)129025380  |0 (DE-627)387778004  |0 (DE-576)297454102  |4 aut 
773 0 8 |i Enthalten in  |t Haematologica  |d Pavia : Ferrata Storti Foundation, 2014  |g 108(2023), 8 vom: Aug., Seite 2059-2066  |h Online-Ressource  |w (DE-627)814204899  |w (DE-600)2805244-4  |w (DE-576)424051125  |x 1592-8721  |7 nnas  |a Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia 
773 1 8 |g volume:108  |g year:2023  |g number:8  |g month:08  |g pages:2059-2066  |g extent:8  |a Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia 
856 4 0 |u https://doi.org/10.3324/haematol.2022.282127  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://haematologica.org/article/view/haematol.2022.282127  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20231016 
993 |a Article 
994 |a 2023 
998 |g 129025380  |a Schlenk, Richard Friedrich  |m 129025380:Schlenk, Richard Friedrich  |d 910000  |d 910100  |e 910000PS129025380  |e 910100PS129025380  |k 0/910000/  |k 1/910000/910100/  |p 32  |y j 
998 |g 1015101798  |a Müller-Tidow, Carsten  |m 1015101798:Müller-Tidow, Carsten  |d 910000  |d 910100  |e 910000PM1015101798  |e 910100PM1015101798  |k 0/910000/  |k 1/910000/910100/  |p 27 
998 |g 108692477  |a Ho, Anthony Dick  |m 108692477:Ho, Anthony Dick  |d 910000  |d 910100  |e 910000PH108692477  |e 910100PH108692477  |k 0/910000/  |k 1/910000/910100/  |p 24 
998 |g 138694923  |a Kayser, Sabine  |m 138694923:Kayser, Sabine  |d 60000  |d 63500  |e 60000PK138694923  |e 63500PK138694923  |k 0/60000/  |k 1/60000/63500/  |p 1  |x j 
999 |a KXP-PPN1865701548  |e 438968826X 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title_sort":"Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia","title":"Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"February 23, 2023","dateIssuedKey":"2023"}],"recId":"1865701548","physDesc":[{"extent":"8 S."}],"id":{"doi":["10.3324/haematol.2022.282127"],"eki":["1865701548"]},"relHost":[{"note":["Gesehen am 27.05.2022"],"disp":"Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemiaHaematologica","id":{"eki":["814204899"],"zdb":["2805244-4"],"issn":["1592-8721"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"814204899","origin":[{"publisherPlace":"Pavia","dateIssuedKey":"2014","publisher":"Ferrata Storti Foundation","dateIssuedDisp":"2014-"}],"titleAlt":[{"title":"journal of the European Hematology Association"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"volume":"108","text":"108(2023), 8 vom: Aug., Seite 2059-2066","year":"2023","issue":"8","extent":"8","pages":"2059-2066"},"language":["eng"],"title":[{"title_sort":"Haematologica","subtitle":"journal of the European Hematology Association : journal of the Ferrata Storti Foundation","title":"Haematologica"}],"pubHistory":["99.2014 -"]}],"note":["Gesehen am 15.11.2023"],"name":{"displayForm":["Sabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, Mathias Hänel, Mar Tormo, Kerstin Schäfer-Eckart, Carmen Botella, Friedrich Stölzel, Teresa Bernal del Castillo, Ulrich Keller, Carlos Rodriguez-Medina, Gerhard Held, Maria-Luz Amigo, Christoph Schliemann, Mercedes Colorado, Martin Kaufmann, Manuel Barrios Garcia, Stefan W. Krause, Martin Görner, Edgar Jost, Björn Steffen, Sven Zukunft, Uwe Platzbecker, Anthony D. Ho, Claudia D. Baldus, Hubert Serve, Carsten Müller-Tidow, Christian Thiede, Martin Bornhäuser, Pau Montesinos, Christoph Röllig and Richard F. Schlenk"]},"person":[{"display":"Kayser, Sabine","given":"Sabine","role":"aut","family":"Kayser"},{"display":"Ho, Anthony Dick","role":"aut","given":"Anthony Dick","family":"Ho"},{"family":"Baldus","given":"Claudia","role":"aut","display":"Baldus, Claudia"},{"family":"Müller-Tidow","given":"Carsten","role":"aut","display":"Müller-Tidow, Carsten"},{"role":"aut","given":"Martin","display":"Bornhäuser, Martin","family":"Bornhäuser"},{"display":"Röllig, Christoph","role":"aut","given":"Christoph","family":"Röllig"},{"display":"Schlenk, Richard Friedrich","given":"Richard Friedrich","role":"aut","family":"Schlenk"}]} 
SRT |a KAYSERSABIIMPACTOFTR2320